MX2021009854A - Compuesto derivado heterociclico novedoso y uso del mismo. - Google Patents

Compuesto derivado heterociclico novedoso y uso del mismo.

Info

Publication number
MX2021009854A
MX2021009854A MX2021009854A MX2021009854A MX2021009854A MX 2021009854 A MX2021009854 A MX 2021009854A MX 2021009854 A MX2021009854 A MX 2021009854A MX 2021009854 A MX2021009854 A MX 2021009854A MX 2021009854 A MX2021009854 A MX 2021009854A
Authority
MX
Mexico
Prior art keywords
derivative compound
same
novel
heterotricyclic
compound
Prior art date
Application number
MX2021009854A
Other languages
English (en)
Inventor
Young Gil Ahn
Seo Hee Kim
Chang Hee Park
Seung Hyun Jung
Dong Jin Hong
Ji Young Hwang
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190019544A external-priority patent/KR102689665B1/ko
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2021009854A publication Critical patent/MX2021009854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se relaciona con compuestos derivados heterotricíclicos novedosos y con el uso de los mismos, y más particularmente, con compuestos derivados heterotricíclicos novedosos que tienen actividad inhibitoria contra la actividad del EZH1 (potenciador de zeste homólogo 1) y/o EZH2 (potenciador de zeste homólogo 2), sales farmacéuticamente aceptables de los mismos, o composiciones farmacéuticas que contienen estos compuestos.
MX2021009854A 2019-02-19 2020-02-19 Compuesto derivado heterociclico novedoso y uso del mismo. MX2021009854A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190019544A KR102689665B1 (ko) 2019-02-19 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
PCT/KR2020/002427 WO2020171606A1 (ko) 2019-02-19 2020-02-19 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2021009854A true MX2021009854A (es) 2021-09-28

Family

ID=72144293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009854A MX2021009854A (es) 2019-02-19 2020-02-19 Compuesto derivado heterociclico novedoso y uso del mismo.

Country Status (16)

Country Link
US (1) US20220135582A1 (es)
EP (1) EP3929199A4 (es)
JP (1) JP7358491B2 (es)
CN (1) CN113423710B (es)
AU (1) AU2020226042B2 (es)
BR (1) BR112021016448A2 (es)
CA (1) CA3130456C (es)
CL (1) CL2021002165A1 (es)
EA (1) EA202191991A1 (es)
IL (1) IL285604A (es)
MX (1) MX2021009854A (es)
PE (1) PE20211703A1 (es)
SG (1) SG11202108940RA (es)
TW (1) TWI829869B (es)
WO (1) WO2020171606A1 (es)
ZA (1) ZA202105970B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP7387907B2 (ja) * 2020-08-13 2023-11-28 ハンミ ファーマシューティカル カンパニー リミテッド 新規なジオキソロイソキノリノン誘導体化合物及びその用途｛ｎｏｖｅｌ ｄｉｏｘｏｌｏｉｓｏｑｕｉｎｏｌｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝
WO2022179584A1 (zh) * 2021-02-26 2022-09-01 南京药石科技股份有限公司 新型ezh2抑制剂及其用途
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
TW202400602A (zh) * 2022-05-31 2024-01-01 大陸商和記黃埔醫藥（上海）有限公司 三環類化合物及其用途
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators
CN115974856B (zh) * 2022-12-28 2023-08-11 北京康立生医药技术开发有限公司 一种治疗成人t细胞白血病淋巴瘤药物伐美妥司他的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2015077194A1 (en) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
PT3121175T (pt) * 2014-03-17 2020-03-05 Daiichi Sankyo Co Ltd Derivados de 1,3-benzodioxol como inibidores de ezh1 e/ou ezh2
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2015193765A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Substituted dihydroisoquinolinone compounds
US10308638B2 (en) 2015-03-25 2019-06-04 The Regents Of The University Of California Selective alpha-7 nicotinic receptor agonists and methods for making and using them
EP3797108B1 (en) * 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP7387907B2 (ja) * 2020-08-13 2023-11-28 ハンミ ファーマシューティカル カンパニー リミテッド 新規なジオキソロイソキノリノン誘導体化合物及びその用途｛ｎｏｖｅｌ ｄｉｏｘｏｌｏｉｓｏｑｕｉｎｏｌｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Also Published As

Publication number Publication date
EP3929199A4 (en) 2022-10-26
SG11202108940RA (en) 2021-09-29
CL2021002165A1 (es) 2022-04-22
AU2020226042B2 (en) 2022-07-14
CN113423710A (zh) 2021-09-21
EA202191991A1 (ru) 2021-12-10
JP7358491B2 (ja) 2023-10-10
AU2020226042A1 (en) 2021-09-09
KR20200101219A (ko) 2020-08-27
IL285604A (en) 2021-09-30
EP3929199A1 (en) 2021-12-29
TWI829869B (zh) 2024-01-21
WO2020171606A1 (ko) 2020-08-27
CN113423710B (zh) 2024-06-14
JP2022522648A (ja) 2022-04-20
BR112021016448A2 (pt) 2021-11-09
PE20211703A1 (es) 2021-09-01
CA3130456C (en) 2023-10-03
ZA202105970B (en) 2023-05-31
CA3130456A1 (en) 2020-08-27
TW202045512A (zh) 2020-12-16
US20220135582A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2021009854A (es) Compuesto derivado heterociclico novedoso y uso del mismo.
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
NZ723312A (en) 1,3-benzodioxole derivative
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MX2021011606A (es) Compuestos dirigidos a prmt5.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
JOP20180094A1 (ar) مركب حلقي غير متجانس كمثبط بروتين كيناز
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021007247A (es) Derivados de rapamicina.
MX2021012105A (es) Compuestos de pirrol.
ZA202100352B (en) Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2021005740A (es) Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
SG11201907945YA (en) Azetidine derivative
EA202190316A1 (ru) Конденсированное производное лактама
ZA202301143B (en) Novel dioxoloisoquinolinone derivatives and use thereof
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2021009717A (es) Sulfonamidas biciclicas.